Edition:
United Kingdom

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

2.00USD
22 Jan 2018
Change (% chg)

$0.05 (+2.56%)
Prev Close
$1.95
Open
$1.90
Day's High
$2.00
Day's Low
$1.90
Volume
4,251
Avg. Vol
31,422
52-wk High
$5.25
52-wk Low
$1.75

Chart for

About

Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $53.93
Shares Outstanding(Mil.): 19.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 28.44 16.58
EPS (TTM): -- -- --
ROI: -- 6.45 10.60
ROE: -- 10.10 14.19

BRIEF-Cancer Genetics Receives Non-Dilutive Funding Of $1.1 Mln

* CANCER GENETICS RECEIVES NON-DILUTIVE FUNDING OF $1.1 MILLION THROUGH NEW JERSEY TECHNOLOGY BUSINESS TAX CERTIFICATE TRANSFER (NOL) PROGRAM

28 Dec 2017

BRIEF-Stonepine Capital Management Reports 5 Percent Passive Stake In Cancer Genetics

* STONEPINE CAPITAL MANAGEMENT REPORTS 5 PERCENT PASSIVE STAKE IN CANCER GENETICS INC AS ON DEC 12 - SEC FILING Source: (http://bit.ly/2p5v6Mx) Further company coverage:

21 Dec 2017

BRIEF-Cancer Genetics Prices $7 Million Registered Direct Offering

* CANCER GENETICS PRICES $7 MILLION REGISTERED DIRECT OFFERING

08 Dec 2017

BRIEF-Cancer Genetics Q3 loss per share $0.15

* Cancer genetics reports record third quarter 2017 revenue and 134% increase in contracted bookings from major biotech and pharmaceutical companies

09 Nov 2017

BRIEF-Cancer Genetics to acquire vivoPharm

* Cancer Genetics announces transformative and accretive acquisition of vivoPharm, a global oncology & immuno-oncology discovery services company

14 Aug 2017

BRIEF-Cancer Genetics reports Q2 loss per share $0.16

* Cancer Genetics Inc announces second quarter 2017 financial results, accretive acquisition and capital raise

14 Aug 2017

BRIEF-DIA elects Cancer Genetics Inc's John A. (Jay) Roberts as Chairman of board

* DIA elects Cancer Genetics Inc's John A(Jay) Roberts as chairman of DIA board of directors

03 Aug 2017

Earnings vs. Estimates